Study of olverembatinib for a rare type of GIST
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, olverembatinib, for GIST that lacks the SDH enzyme and has gotten worse after at least one prior treatment. It aims to see if the drug can stop or shrink the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have GIST with loss of SDHB (a specific enzyme marker) and at least one prior treatment stopped working or caused side effects.
- You have at least one tumor that can be measured on scans.
- You are able to care for yourself (ECOG score 0-2) and expected to live at least 3 months.
- You have adequate organ function (kidneys, liver, etc.) as determined by your doctor.
- You are not pregnant, and you and your partner agree to use effective contraception during and for 30 days after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests inlexisertib (a targeted cancer drug) combined with other anticancer treatments in adults with advanced GIST. It is mainly looking for safety and the best way to dose, and it may help tumors that have certain KIT or PDGFRA gene changes.
This trial tests a drug called lenvatinib for people with advanced GIST that has not responded to three previous treatments. It may offer a new option if standard therapies have stopped working or caused severe side effects.
This trial studies avapritinib, a targeted medicine, for people with advanced or returning gastrointestinal stromal tumors (GIST) whose tumor does not have PDGFRA exon 18 mutations. It aims to see how well the drug can shrink tumors or control the disease.
This trial tests a drug called pemigatinib for people with a specific type of GIST (SDH-deficient GIST) that has spread or cannot be removed with surgery. The goal is to see if the drug can help stop the cancer from growing.
This trial tests a new drug called velzatinib for people with advanced gastrointestinal stromal tumor (GIST) that has spread or cannot be removed by surgery. It is for those whose cancer has worsened after trying several standard treatments.
This trial compares a newer cancer drug (velzatinib) with a standard treatment (imatinib) for gastrointestinal stromal tumors (GIST) that cannot be surgically removed or have spread. You would receive one of these two drugs to see which works better and is safer.
Hear when a new GIST trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.